【ChiCTR2100045102】EFFECTS OF PERIOPERATIVE INFLAMMATORY RESPONSE IN CERVICAL CANCER: LAPAROSCOPIC VERSUS OPEN SURGERY
ChiCTR2100045102
正在进行
/
/
/
2021-04-06
/
/
宫颈癌
EFFECTS OF PERIOPERATIVE INFLAMMATORY RESPONSE IN CERVICAL CANCER: LAPAROSCOPIC VERSUS OPEN SURGERY
Postoperative NLR and survival in cervical cancer
To compare postoperative changes in NLR according to surgical methods and determine the effect of these changes on 5-year survival of cervical cancer patients.
连续入组
回顾性研究
No randomization Procedure
N/A
The author's own work
/
929
/
2020-11-01
2021-12-31
/
Patients who underwent ORH or LRH between June 2006 and February 2015.Adult female patients aged ≥18 years were included in the study.；
请登录查看1. Patients who had severe diseases such as cardiovascular disease, hematologic disease, inflammatory disease, and other malignancies; 2. Patients who have received any cervical neoplasia treatment prior to the admission; 3. Patients who converted from laparoscopic surgery to laparotomy; 4. Patients with incomplete data from medical records.；
请登录查看The author's own work
/
The author's own work的其他临床试验
韩国峨山医疗中心Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04